Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Rises By 301.8%

Windtree Therapeutics, Inc. (NASDAQ:WINT) saw a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 195,700 shares, a growth of 301.8% from the October 15th total of 48,700 shares. Currently, 2.4% of the company’s shares are short sold. Based on an average daily volume of 1,660,000 shares, the short-interest ratio is presently 0.1 days.

Windtree Therapeutics Stock Down 6.2 %

Shares of NASDAQ WINT opened at $0.53 on Thursday. The business has a fifty day simple moving average of $1.70 and a 200-day simple moving average of $4.20. The company has a market cap of $311,402.00, a price-to-earnings ratio of -0.02 and a beta of 0.64. Windtree Therapeutics has a 12 month low of $0.53 and a 12 month high of $22.36.

Windtree Therapeutics (NASDAQ:WINT) last announced its earnings results on Monday, August 19th. The company reported ($20.91) EPS for the quarter, missing the consensus estimate of ($8.11) by ($12.80). As a group, sell-side analysts expect that Windtree Therapeutics will post -2.38 EPS for the current fiscal year.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.